Imatinib activity on Schistosoma mansoni

Memorias do Instituto Oswaldo Cruz

Volumn 108, Issue 7, 2013, Pages 850-853

  Katz, Naftale ^a,b   Couto, Flávia Fernanda Bubulo ^a   Araújo, Neusa ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Academia Mineira de Medicina   (Brazil)

Author keywords

Chemotherapy; Imatinib; Schistosomiasis

Indexed keywords

ANTISCHISTOSOMAL AGENT; BENZAMIDE DERIVATIVE; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL; DOSE RESPONSE; DRUG EFFECTS; MOUSE; PARASITE LOAD; PARASITOLOGY; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; TIME;

ANIMALS; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; PARASITE LOAD; PIPERAZINES; PYRIMIDINES; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SCHISTOSOMICIDES; TIME FACTORS;

EID: 84886885452     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/0074-0276130207     Document Type: Article

References (28)

1. Andersen ML, D'Almeida Vânia, Gui Mi KO, Kawakami R, Martins PJF, Magalhães L, Tufik S 2004. Principios éticos e práticos do uso de animais de experimentação, CLR Balieiro, São Paulo, 167 pp.
2. Araújo N, de Mattos ACA, Coelho PMZ, Katz N 2008. Association of oxamniquine, praziquantel and clonazepam in the experimental schistosomiasis mansoni. Mem Inst Oswaldo Cruz 103: 781-785.
3. Beckmann S, Grevelding CG 2010. Imatinib has a fatal impact on morphology, pairing stability and survival of adult Schistosoma mansoni in vitro. Int J Parasitol 40: 521-526.
4. Beckmann S, Hahnel S, Cailliau K, Vanderstraet M, Browaeys E, Dissous C, Grevelding CG 2011. Characterization of the Src/Abl hybrid kinase SmTK6 of Schistosoma mansoni. J Biol Chem 286: 42325-42336.
5. Bonesso-Sabadini PIP, Dias LCS 2002. Altered response of Schistosoma mansoni to oxamniquine and praziquantel. Mem Inst Oswaldo Cruz 97: 381-385.
6. Bruun B, Aagaard-Hansen J 2008. The social context of schistosomiasis and its control: an introduction and annotated bibliography, World Health Organization, Geneve, 213 pp.
7. Cohen P 2009. Targeting protein kinases for the development of antiinflammatory drugs. Curr Opin Cell Biol 21: 317-324.
8. Dissous C, Ahier A, Khayath N 2007. Protein tyrosine kinases as new potential targets against human schistosomiasis. Byoessays 29: 281-288.
9. Doenhoff MJ, Cioli D, Utzinger J 2008. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21: 659-667.
10. El-Agamy DS, Shebl AM, Said AS 2011. Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice. Inflammopharmacology 19: 307-316.
11. Fonseca CT, Cunha-Neto E, Goldberg AC, Kalil J, Jesus AR, Carvalho EM, Correa-Oliveira R, Oliveira SC 2005. Human T cell epitope mapping of the Schistosoma mansoni 14kDa fatty acidbinding protein using cells from patients living in areas endemic for schistosomiasis. Microbes Infect 7: 204-212.
12. Hemer S, Brehm K 2012. In vitro efficacy of the anticancer drug imatinib on Echinococcus multilocularis larvae. Int J Antimicrob Agents 40: 458-462.
13. Katz N, Almeida K 2003. Esquistossomose, xistosa, barriga d'água. Cienc Cult 55: 38-43.
14. Knobloch J, Beckmann S, Burmeister C, Quack T, Grevelding CG 2007. Tyrosine kinase and cooperative TGF beta signaling in the reproductive organs of Schistosoma mansoni. Exp Parasitol 117: 318-336.
15. Kretz O, Weiss MH, Schumacher MM, Gross G 2004. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 2: 212-216.
16. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y 2008. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111: 4022-4028.
17. Mahanty S, Madrid EM, Nash TE 2012. Quantitative screening for anticestode drugs based on changes in baseline enzyme secretion by Taenia crassiceps. Antimicrob Agents Chemother 57: 990-995.
18. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mutuku MW, Karanja DMS, Colley DG, Black CL, Secor WE, Mkoji GM, Loker ES 2009. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS NTDi 3: e504.
19. Naula C, Parsons M, Mottram JC 2005. Protein kinases as drugs targets in trypanosomes and Leishmania. Biochim Biophys Acta 1754: 151-159.
20. Pellegrino J, Katz N 1968. Experimental chemotherapy of schistosomiasis mansoni. Adv Parasitol 6: 233-290.
21. Pellegrino J, Oliveira CA, Faria J, Cunha AS 1962. New approach to the screening of drugs in experimental Schistosoma mansoni in mice. Am J Trop Med Hyg 11: 201-215.
22. Pellegrino J, Siqueira AF 1956. Técnica de perfusão para colheita de Schistosoma mansoni em cobaias experimentalmente infectadas. Rev Bras Malariol 8: 589-597.
23. Qi L, Cui J 2013. A schistosomiasis model with praziquantel resistance. Discrete Dynamics in Nature and Society 2013: ID 945767.
24. Savage DG, Antman KH 2002. Imatinib mesylate: a new oral targeted therapy. N Eng J Med 346: 683-693.
25. Smithers SR, Terry RJ 1965. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of adult worms. Parasitol 55: 695-700.
26. Tsai MH, Marx KA, Ismail MM, Tao LF 2000. Randomly amplified polymorphic DNA (RAPD) polymerase chain reaction assay for identification of Schistosoma mansoni strains sensitive or tolerant to anti-schistosomal drugs. J Parasitol 86: 146-149.
27. Ward P, Equinet L, Packer J, Doerig C 2004. Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote. BMC Genomics 5: 79.
28. William S, Sabra A, Ramzy F, Mousa M, Demerdash Z, Bennett JL, Day TA, Botros S 2001. Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel. Int J Parasitol 31: 1093-100.